Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension.
نویسندگان
چکیده
PURPOSE Prostaglandin F(2alpha) analogues, such as latanoprost, may cause a decrease in the extracellular matrices, such as collagen, and changes in fibrillin-1; both are components of the ciliary zonules. However, the mechanical effect of these changes on the dynamics of the ciliary zonules is unknown. This study was conducted to evaluate the effect of latanoprost 0.005% on anterior chamber depth (ACD), best corrected visual acuity (BCVA), lens thickness, and anterior chamber dynamics in patients with glaucoma or ocular hypertension. METHODS This was a prospective, nonrandomized, autocomparative trial that included 40 patients (40 eyes) with glaucoma or ocular hypertension. ACD was measured with ultrasonography before and after 1 month of treatment with latanoprost. In addition, ACD was measured before and 1 hour after instillation of pilocarpine 2% at baseline and 1 month after treatment with latanoprost. To assess the reproducibility of the ultrasonic measurements, a control group of 20 patients (20 eyes) who did not receive latanoprost was also analyzed. RESULTS The mean ACD before treatment with latanoprost and before the instillation of pilocarpine was 3.14 +/- 0.46 mm (SD) and after the instillation of pilocarpine, 3.04 +/- 0.46 mm (SD). After 1 month of treatment with latanoprost, ACD was 2.98 +/- 0.44 mm (SD) before instillation of pilocarpine and 2.91 +/-0.49 mm (SD) after instillation of pilocarpine. P < or = 0.05 was reached for all comparisons. CONCLUSIONS These findings suggest that latanoprost decreases ACD in patients with glaucoma or ocular hypertension after 1 month of treatment.
منابع مشابه
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension
In an elegant example of bench-to-bedside research, a hypothesis that cells in the outflow pathway actively regulate conventional outflow resistance was proposed in the 1990s and systematically pursued, exposing novel cellular and molecular mechanisms of intraocular pressure (IOP) regulation. The critical discovery that pharmacologic manipulation of the cytoskeleton of outflow pathway cells dec...
متن کاملThe Biometric Values of Affected and Fellow Eyes in Patients with Acute Attack of Primary Angle Closure
Background: It has been estimated that 67 million people worldwide are affected with a primary glaucoma and that one-third have primary angle closure glaucoma. We aimed to determine the biometric differences between the eyes of patients with acute attack of primary angle closure and their non-involved fellow eyes. Methods: Twenty eight patients with acute attack of primary angle closure were re...
متن کاملLatanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
Latanoprost is a prostaglandin F2-alpha isopropyl ester prodrug which is rapidly hydrolyzed by esterases in the cornea to the biologically active latanoprost acid. When latanoprost is topically administered into the eye, the cornea seems to act like as a slow-release depot to the anterior segment. One hour after administration maximum concentration is found in the iris, followed by the anterior...
متن کاملLatanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.
PURPOSE To determine efficacy and safety of latanoprost, a prostaglandin analog for glaucoma, during 1 year of treatment. METHODS After baseline measurements, 0.005% latanoprost was topically applied once daily for 12 months in patients from Scandinavia, the United Kingdom, and the United States who had elevated intraocular pressure (IOP). Diagnoses included ocular hypertension, chronic open-...
متن کاملEffects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension.
AIMS To evaluate whether long-term treatment with the prostaglandin analogue latanoprost has a deleterious effect on the blood-aqueous barrier (BAB) and to determine the duration of the effect on intraocular pressure (IOP) after withdrawal of treatment. METHODS Patients with ocular hypertension or glaucoma were topically treated with latanoprost 50 micrograms/ml once daily for 6-12 months. In...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Investigative ophthalmology & visual science
دوره 47 11 شماره
صفحات -
تاریخ انتشار 2006